ZERO

ZERO Prostate Cancer Promotes Early Detection as a National Priority During Prostate Cancer Awareness Month

Retrieved on: 
Tuesday, August 29, 2023
Risk, National Prostate Health Month, Prostate cancer, Education, Cancer, ZERO, Screening, American Cancer Society, Disease, Dairy

WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- ZERO Prostate Cancer urges men to learn about their prostate cancer risks and early detection during Prostate Cancer Awareness Month, beginning September 1. According to the American Cancer Society, 3.1 million+ men live with prostate cancer, making it the most commonly diagnosed cancer and one of the leading causes of cancer deaths among American men.

Key Points: 
  • WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- ZERO Prostate Cancer urges men to learn about their prostate cancer risks and early detection during Prostate Cancer Awareness Month , beginning September 1.
  • According to the American Cancer Society , 3.1 million+ men live with prostate cancer, making it the most commonly diagnosed cancer and one of the leading causes of cancer deaths among American men.
  • "Prostate Cancer Awareness Month elevates the urgency of early detection.
  • ZERO Prostate Cancer Day will be held on September 28, encouraging donations and sharing of life-saving messages.

Brenmiller Received Approval to Supply Israel's Wolfson Hospital with Breakthrough Sustainable Electric Heat

Retrieved on: 
Tuesday, August 29, 2023
Other Energy, Environment, Utilities, Sustainability, Alternative Energy, Energy, Electricity, TES, Carbon, ZERO, Ministry, Steam, Hospital, Patient, Nursing, TASE, NIS

Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy”) (Nasdaq: BNRG; TASE: BNRG), a global leader in thermal energy storage (“TES”), today announced that it has received final approval from the Israeli Ministry of Finance to supply electric process heat to Wolfson Hospital, a public medical center located near Tel Aviv in Holon, Israel.

Key Points: 
  • Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy”) (Nasdaq: BNRG; TASE: BNRG), a global leader in thermal energy storage (“TES”), today announced that it has received final approval from the Israeli Ministry of Finance to supply electric process heat to Wolfson Hospital, a public medical center located near Tel Aviv in Holon, Israel.
  • The Israeli Ministry of Finance announced it has approved a budget of up to NIS 14 million (approximately US$3.7 million) for Wolfson Hospital to procure TES equipment from Brenmiller.
  • A final agreement between Wolfson Hospital and Brenmiller is under preparation (the “Agreement”) and is expected to be signed by the end of Q4 2023.
  • Subject to negotiation and execution of the definitive Agreement, Brenmiller will deliver its technology and supply heat to Wolfson Hospital at zero up-front cost through an agreement for a seven-year term.

For Realizing Vision of ZERO Cerebro-Cardiovascular Events, OMRON Healthcare Sponsors First Annual Meeting of AF Screen International Collaboration

Retrieved on: 
Tuesday, August 29, 2023
Concord Hospital, University, Hypertension, Stroke, Ageing, World Health Organization, ECG, Research, Heart Research Institute, Cerebro, ZERO, Patient, Physician, Risk, WHO, AF, Death, Disease, Pharmaceutical industry, Cardiology

A World Health Organization (WHO) report shows that the global leading cause of death is heart disease, followed by stroke.

Key Points: 
  • A World Health Organization (WHO) report shows that the global leading cause of death is heart disease, followed by stroke.
  • In addition, the OMRON Academy, a learning program for healthcare professionals, has been actively implemented to raise awareness of the disease.
  • The Company sponsored the first annual meeting of the AF Screen International Collaboration, and during the meeting, physicians presented the latest findings in early detection of AF as well as the risk of developing AF in hypertensive patients and agreed to jointly conduct future disease awareness activities.
  • For realizing the vision of Going for ZERO, achieving zero cerebro-cardiovascular events, the Company has committed to supporting a better hypertension treatment and early detection of AF in collaboration with healthcare professionals and researchers.

FILEDOGE (FILEDOGE) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Sunday, August 27, 2023
Bitcoin, Ethereum, SHIB, DOGE, FIL, Culture, MEME, ZERO, Discord, Non-fungible token, EAT, DEX, Cryptocurrency, Filecoin

Road Town, British Virgin Islands--(Newsfile Corp. - August 26, 2023) - LBank Exchange, a global digital asset trading platform, listed FILEDOGE (FILEDOGE) on August 27, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - August 26, 2023) - LBank Exchange, a global digital asset trading platform, listed FILEDOGE (FILEDOGE) on August 27, 2023.
  • For all users of LBank Exchange, the FILEDOGE/USDT trading pair is now officially available for trading.
  • Anchored by Filecoin's programmable smart contracts, FILEDOGE introduces a fair, community-driven approach to its launch, contrasting traditional centralized teams.
  • Amid the rise of Web 3.0, where these elements intertwine, FILEDOGE emerges as a social experiment, encapsulating the spirit of creation, innovation, and decentralized organization.

Brenmiller Plans to Ramp Sales Across Europe Through New Joint Venture with Green Enesys and Viridi

Retrieved on: 
Wednesday, August 23, 2023
Other Energy, Environment, Utilities, Sustainability, Alternative Energy, Energy, Partnership, BofA Securities, Electricity, TES, Arieta Enesi Mulitauaopele, Cloud computing, Negotiation, ZERO, JV, Thermal energy storage, TASE, Natural gas, Engineering, European Investment Bank, Renewable energy, Viridi, European

Establishing the JV and the activities contemplated by the JV are subject to negotiating and execution of definitive agreements.

Key Points: 
  • Establishing the JV and the activities contemplated by the JV are subject to negotiating and execution of definitive agreements.
  • “Green Enesys and Viridi are professional and reliable partners for us, with a proven track record for delivering significant renewable generation worldwide.
  • Importantly, they share our commitment to helping decarbonize industrial heat production,” said Avi Brenmiller, CEO and Chairman of the Board of Brenmiller Energy.
  • Brenmiller’s award-winning bGen™ ZERO is a mature, scalable, and cost-effective way to convert electricity into heat to provide industrial process power and enable 24/7 renewable management.

U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, August 14, 2023
Biotechnology, Pharmaceutical, Men, Oncology, Health, FDA, Genetics, Consumer, Prostate cancer, NGS, Cancer, Janssen, ZERO, Doctor of Philosophy, MD, Patient, BRCA, Foundation Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Education, Food, Medical imaging

Using a tissue sample, the FDA-approved FoundationOne CDx test analyzes more than 300 cancer-related genes for genomic alterations in a patient’s tumor.

Key Points: 
  • Using a tissue sample, the FDA-approved FoundationOne CDx test analyzes more than 300 cancer-related genes for genomic alterations in a patient’s tumor.
  • The test currently has over 30 companion diagnostic indications.
  • The company also has 60% of all U.S. companion diagnostic approvals for next generation sequencing (NGS) testing.
  • “This companion diagnostic specifically will help enable broader access to an important new therapy option in BRCA1/2+ mCRPC.

U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Friday, August 11, 2023
DSM-IV codes, Janssen Pharmaceuticals, Neoplasm, AE, Prostate cancer, Abiraterone acetate, CI, Drug, Constipation, BC Cancer Agency, Janssen, Prognosis, Mutation, AAP, RPF, CHES, ZERO, Science, Hypertension, Prednisone, Death, TCC, Patient, Hazard, TSP, Medicine, Cancer, HR, Genetic testing, Nausea, IA2, Johnson & Johnson, BRCA, FDA, PARP, Education, Disease, Safety, Fatigue, Pharmaceutical industry, Medical imaging, HORSHAM

HORSHAM, Pa., Aug. 11, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food & Drug Administration (FDA) has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.1

Key Points: 
  • *, Medical Oncologist at BC Cancer – Vancouver and principal investigator of the Phase 3 MAGNITUDE study.
  • "All individuals diagnosed with prostate cancer should consider genetic testing, especially those from racial and ethnic minority groups who tend to have worse cancer outcomes.
  • This is imperative to close the racial and ethnic disparities in prostate cancer health outcomes."
  • "This milestone, which marks the approval of Janssen's third prostate cancer treatment, highlights the importance of advancing precision medicine approaches and genetic testing for the treatment of patients with BRCA-positive mCRPC."

Brenmiller Energy Reports Operational Update and Financial Results for the Six Months Ended June 30, 2023

Retrieved on: 
Friday, August 11, 2023
Other Energy, Environment, Utilities, Alternative Energy, Green Technology, Energy, Term sheet, Tel Aviv Stock Exchange, BofA Securities, Ball State Center for Energy Research/Education/Service, TES, Research, Cloud computing, ZERO, Consultant, Government, Kilowatt-hour, Ministry, Environmental protection, Steam, Climate change, TASE, Engineering, Memorandum of understanding, Depreciation, EIB, European Investment Bank, Cryptocurrency, Renewable energy

Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy”) (Nasdaq: BNRG; TASE: BNRG), a global leader in thermal energy storage (“TES”), today announced financial results as of and for the six months ended June 30, 2023, in addition to operational and recent business development updates.

Key Points: 
  • Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy”) (Nasdaq: BNRG; TASE: BNRG), a global leader in thermal energy storage (“TES”), today announced financial results as of and for the six months ended June 30, 2023, in addition to operational and recent business development updates.
  • Decarbonization of heat is the low hanging fruit of fighting climate change, as heat is the largest energy end-use,” stated Avi Brenmiller, Chairman and Chief Executive Officer of Brenmiller Energy.
  • This decrease was offset by a net decrease of $0.17 million in government grants received in the six months ended June 30, 2023, compared to the six months ended June 30, 2022.
  • The Company expects research, development, and engineering expenses will remain similar to those during the period ended June 30, 2023.

Startup NiHowdy Launches Revolutionary Platform to Save on Prescription Drugs and Earn Bitcoin

Retrieved on: 
Thursday, August 10, 2023
Elijah Cummings Lower Drug Costs Now Act, Coinbase, Pharmacy, Map, ZERO, Cryptocurrency, Online shopping, Health insurance, Pharmaceutical industry, Bitcoin

This revolutionary platform offers users a modern value proposition: substantial savings on their prescription medications complemented by Bitcoin rebates on each purchase.

Key Points: 
  • This revolutionary platform offers users a modern value proposition: substantial savings on their prescription medications complemented by Bitcoin rebates on each purchase.
  • Users can search for their prescription drugs on the NiHowdy website, compare prices, and find the cheapest locations to purchase their medication.
  • To start earning Bitcoin rebates while saving on your prescription medications, visit NiHowdy.com and sign up to receive your personal prescription discount card.
  • As NiHowdy gears up to redefine prescription drug costs and delivery, the innovative healthcare landscape has found a remarkable new player.

Florida's First 'Guntry' Club Opens in Fort Lauderdale

Retrieved on: 
Thursday, August 10, 2023
ZERO, Curriculum, HEPA, VIP, Multimedia, Safety, Nightclub, Apex

"We're pleased to bring South Florida the very first, next-generation shooting center for  private members," said Founders and Apex owner, Victor Grillo.

Key Points: 
  • "We're pleased to bring South Florida the very first, next-generation shooting center for  private members," said Founders and Apex owner, Victor Grillo.
  • "Like our sister facility in Boston, the Weston Shooters Club, we wanted Florida to have its first ever 'guntry'-style club.
  • Founders Shooting Club is the only "green" range in Florida and offers 100% recyclable products with ZERO environmental impact.
  • To learn more about becoming a member of Founders Shooting Club, visit
    View original content to download multimedia: https://www.prnewswire.com/news-releases/floridas-first-guntry-club-open...